Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks
ID:am030003M0035267mhji5📫 -页
内容摘要
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks
海外数据平台所有内容均是公开网络、AI代理代查、客户上传分享、合作方,仅供网友学习交流,请勿商用!

